NO20033665L - Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer - Google Patents

Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer

Info

Publication number: NO20033665L
Authority: NO; Norway
Prior art keywords: malonyl; azoles; coa decarboxylase; compounds; inhibitors useful
Prior art date: 2001-02-20

Application number

NO20033665A

Other languages

English (en)

Norwegian (no)

Other versions

NO20033665D0 (no

Inventor

Thomas Arrhenius

Jie Fei Cheng

Mark Wilson

Rossy Serafimov

Gary D Lopaschuk

Jason R Dyck

Alex M Nadzan

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-20

Filing date

2003-08-19

Publication date

2003-10-20

2003-08-19 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2003-08-19 Publication of NO20033665D0 publication Critical patent/NO20033665D0/no

2003-10-20 Publication of NO20033665L publication Critical patent/NO20033665L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20033665A 2001-02-20 2003-08-19 Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer NO20033665L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27003401P	2001-02-20	2001-02-20
PCT/US2002/004777 WO2002066035A2 (fr)	2001-02-20	2002-02-19	Azoles en inhibiteurs de la décarboxylase des malonyl-coa, convenant comme modulateurs métaboliques

Publications (2)

Publication Number	Publication Date
NO20033665D0 NO20033665D0 (no)	2003-08-19
NO20033665L true NO20033665L (no)	2003-10-20

Family

ID=23029607

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033665A NO20033665L (no)	2001-02-20	2003-08-19	Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer

Country Status (23)

Country	Link
US (1)	US7723366B2 (fr)
EP (2)	EP1370260B1 (fr)
JP (4)	JP4155351B2 (fr)
KR (1)	KR100659427B1 (fr)
CN (1)	CN100383132C (fr)
AT (2)	ATE489089T1 (fr)
AU (1)	AU2002251987B2 (fr)
BR (1)	BR0207408A (fr)
CA (1)	CA2437409C (fr)
CY (1)	CY1110986T1 (fr)
DE (2)	DE60233650D1 (fr)
DK (1)	DK1370260T3 (fr)
ES (2)	ES2353686T3 (fr)
HU (1)	HU229431B1 (fr)
IL (2)	IL156827A0 (fr)
MX (1)	MXPA03007441A (fr)
NO (1)	NO20033665L (fr)
NZ (1)	NZ526883A (fr)
PL (1)	PL204456B1 (fr)
PT (1)	PT1370260E (fr)
RU (1)	RU2258706C2 (fr)
SI (1)	SI1370260T1 (fr)
WO (2)	WO2002066034A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7709510B2 (en)	2001-02-20	2010-05-04	Chugai Seiyaku Kabushiki Kaisha	Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
MXPA03007441A (es)	2001-02-20	2004-10-15	Chugai Pharmaceutical Co Ltd	Azoles como inhibidores de malonil-coa descarboxilasa utiles como modulares metabolicos.
WO2003090746A1 (fr) *	2002-04-23	2003-11-06	Chugai Seiyaku Kabushiki Kaisha	1,3-thiazoles utilises en tant que modulateurs du lxr pour le traitement de maladies cardiovasculaires
EP1648564B1 (fr) *	2003-08-01	2007-10-17	Chugai Seiyaku Kabushiki Kaisha	Composes de cyanoamide utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase
ES2353306T3 (es) *	2003-08-01	2011-03-01	Chugai Seiyaku Kabushiki Kaisha	Compuestos heterocíclicos útiles como inhibidores de la malonil-coa-descarboxilasa.
DE602004014937D1 (de) *	2003-08-01	2008-08-21	Chugai Pharmaceutical Co Ltd	Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
JP4773960B2 (ja) *	2003-08-01	2011-09-14	中外製薬株式会社	マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノグアニジン型アゾール化合物
ES2564167T3 (es)	2004-07-08	2016-03-18	Novo Nordisk A/S	Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
RU2425834C2 (ru) *	2005-11-08	2011-08-10	Ф. Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ТИАЗОЛО[4,5-c]ПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ mGluR5
JP5405120B2 (ja) *	2006-12-01	2014-02-05	Ｍｓｄ株式会社	新規フェニル−イソキサゾール−３−オール誘導体
WO2009147990A1 (fr) *	2008-06-02	2009-12-10	萬有製薬株式会社	Nouveau dérivé d'isoxazole
AU2011239386B2 (en)	2010-04-16	2015-03-19	Salk Institute For Biological Studies	Methods for treating metabolic disorders using FGF
AU2014340241B2 (en) *	2013-10-21	2018-11-01	Salk Institute For Biological Studies	Mutated fibroblast growth factor (FGF) 1 and methods of use
WO2015061331A1 (fr)	2013-10-21	2015-04-30	Salk Institute For Biological Studies	Peptides de facteur de croissance des fibroblastes (fgf) 2/fgf1 chimériques et procédés d'utilisation
EP3368059A4 (fr)	2015-10-30	2019-03-27	Salk Institute for Biological Studies	Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
JOP20190024A1 (ar)	2016-08-26	2019-02-19	Gilead Sciences Inc	مركبات بيروليزين بها استبدال واستخداماتها
EP4092013A1 (fr)	2017-06-20	2022-11-23	Imbria Pharmaceuticals, Inc.	Compositions et procédés pour augmenter l'efficacité du métabolisme cardiaque
EP3759109B1 (fr)	2018-02-26	2023-08-30	Gilead Sciences, Inc.	Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b
US12318382B2 (en)	2018-10-17	2025-06-03	Imbria Pharmaceuticals, Inc.	Methods of treating rheumatic diseases using trimetazidine-based compounds
US11542309B2 (en)	2019-07-31	2023-01-03	Salk Institute For Biological Studies	Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11780811B2 (en)	2020-06-30	2023-10-10	Imbria Pharmaceuticals, Inc.	Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en)	2020-06-30	2022-12-20	Imbria Pharmaceuticals, Inc.	Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en)	2021-05-03	2024-01-30	Imbria Pharmaceuticals, Inc.	Methods of treating kidney conditions using modified forms of trimetazidine
CN114767665B (zh) *	2021-06-11	2023-10-10	同济大学	5-十四烷氧基-2-呋喃甲酸在制备用于治疗银屑病样皮炎的药物中的用途

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2863874A (en)	1955-05-26	1958-12-09	Goodrich Co B F	Process of preparing 2-aminothiazoles
US3728455A (en) *	1971-06-24	1973-04-17	American Cyanamid Co	Novel compositions of matter
EP0144101B1 (fr)	1983-11-30	1991-02-06	Janssen Pharmaceutica N.V.	N-(Hétérocycle bicyclyl)-4-pipéridinamines contenant des hétérocycles bicycliques
JPS60202872A (ja)	1984-03-27	1985-10-14	Kaken Pharmaceut Co Ltd	ベンゾフラン誘導体、その製法およびそれを有効成分とする降圧剤
CA1281325C (fr)	1984-06-20	1991-03-12	Patrice C. Belanger	Derives de benzofurane
US4783443A (en)	1986-03-03	1988-11-08	The University Of Chicago	Amino acyl cephalosporin derivatives
GB8714537D0 (en)	1987-06-22	1987-07-29	Ici Plc	Pyrazine derivatives
EP0733366B1 (fr)	1988-01-07	1998-04-01	E.I. Du Pont De Nemours And Company	Compositions pharmaceutiques comprenant des imidazoles comme antagonistes d'angiotensine II et des diurétiques
EP0479903B1 (fr)	1989-06-30	1996-02-21	E.I. Du Pont De Nemours And Company	Imidazoles substitues utiles comme inhibiteurs de l'angiotensin ii
WO1991000281A2 (fr)	1989-06-30	1991-01-10	E.I. Du Pont De Nemours And Company	Imidazoles a substitution aryle a anneau fusionne
SU1681502A1 (ru)	1989-07-26	1994-06-15	Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе	Гидрохлорид 3-(2,5- диметоксибензоил) -4- диметиламинометил -5-окси-6- бромбензофурана, обладающий анальгетическим, местноанестезирующим, противосудорожным, противоаритмическим, стимулирующим коронарный, мозговой и почечный кровоток действиями
RU1743153C (ru)	1990-06-04	1995-02-27	ВНИИ химических средств защиты растений	N-[4-2'-гидроксигексафторизопропил)фенил] -n-этил-n'-фенилмочевина, обладающая рострегулирующим и антидотным действием
DK0533840T3 (da)	1990-06-22	1996-12-30	Du Pont	Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister
US5428033A (en)	1990-10-12	1995-06-27	Merck Frosst Canada, Inc.	Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5470975A (en)	1990-10-16	1995-11-28	E.R. Squibb & Sons, Inc.	Dihydropyrimidine derivatives
CA2053148A1 (fr)	1990-10-16	1992-04-17	Karnail Atwal	Derives de la dihydropyrimidine
US5374615A (en)	1990-10-31	1994-12-20	E. R. Squibb & Sons, Inc.	Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
SU1825496A3 (ru)	1991-04-04	1994-12-30	Всесоюзный научно-исследовательский институт химических средств защиты растений	Производные n-[4-(1-гидрокси-1-трифторметил-2,2,2-трифторэтил)фенил]мочевины, обладающие антидотной активностью к 2-хлор-n-[(4-метокси-6-метил-1,3,5-триазин-2-ил)аминокарбонил] бензолсульфамиду в посевах льна
IT1245712B (it) *	1991-04-09	1994-10-14	Boehringer Mannheim Italia	Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
JPH05124925A (ja) *	1991-04-09	1993-05-21	Sansho Seiyaku Co Ltd	メラニン生成抑制外用剤
US5190942A (en)	1991-04-22	1993-03-02	E. R. Squibb & Sons, Inc.	Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
US5177097A (en)	1991-07-24	1993-01-05	E. R. Squibb & Sons, Inc.	Acyl amidine and acyl, guanidine substituted biphenyl derivatives
US5256695A (en)	1991-07-24	1993-10-26	E. R. Squibb & Sons, Inc.	Acyl amidine and acyl guanidine substituted biphenyl derivatives
EP0601039A1 (fr)	1991-08-19	1994-06-15	E.I. Du Pont De Nemours And Company	Derives d'imidazolinone d'inhibition de l'action de l'angiotensine ii au niveau de ses recepteurs
US5212177A (en)	1991-12-16	1993-05-18	E. R. Squibb & Sons, Inc.	Indole and benzimidazole-substituted dihydropyrimidine derivatives
US5350752A (en)	1991-12-16	1994-09-27	E. R. Squibb & Sons, Inc.	Dihydropyrimidine derivatives
US5225408A (en)	1991-12-20	1993-07-06	E. R. Squibb & Sons, Inc.	Biphenyl oxadiazinone angiotensin II inhibitors
TW297025B (fr)	1992-02-14	1997-02-01	Squibb & Sons Inc
US5208234A (en)	1992-03-10	1993-05-04	E. R. Squibb & Sons, Inc.	Substituted imidazole phosphonic and phosphinic acid derivatives
US5208235A (en)	1992-03-10	1993-05-04	E. R. Squibb & Sons, Inc.	Indole- and benzimidazole-substituted imidazole derivatives
AU3884893A (en)	1992-04-10	1993-11-18	Merck Frosst Canada Inc.	Thiazole-substituted benzyl alcohols as leukotriene antagonists
US5506227A (en)	1992-04-13	1996-04-09	Merck Frosst Canada, Inc.	Pyridine-substituted benzyl alcohols as leukotriene antagonists
US5378704A (en)	1992-04-15	1995-01-03	E. R. Squibb & Sons, Inc.	Non-peptidic angiotensin-II-receptor-antagonists
US5534347A (en)	1992-09-04	1996-07-09	Eastman Kodak Company	Fusing roll having a fluorocarbon-silicone barrier layer
CA2147990C (fr)	1992-10-30	2001-02-20	Keith D. Weiss	Produits magnetorheologiques de faible viscosite
GB9226860D0 (en)	1992-12-23	1993-02-17	Leo Pharm Prod Ltd	Novel treatment
DE9422447U1 (de)	1993-01-15	2002-10-17	G.D. Searle LLC, Chicago, Ill.	3,4-Diarylthiophene und Analoga davon, sowie deren Verwendung als entzündungshemmende Mittel
DE4302681A1 (de)	1993-02-01	1994-08-04	Hoechst Ag	Sulfonsäureester, damit hergestellte strahlungsempfindliche Gemische und deren Verwendung
DE4306152A1 (de)	1993-02-27	1994-09-01	Hoechst Ag	Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
JPH07188227A (ja)	1993-12-24	1995-07-25	Japan Tobacco Inc	チアゾリジン誘導体及びオキサゾール誘導体
WO1995020950A1 (fr)	1994-02-03	1995-08-10	Cambridge Neuroscience, Inc.	Guanidines therapeutiques
US5519040A (en)	1994-04-29	1996-05-21	Allergan	Substituted thiazole sulfonamides as antiglaucoma agents
US5932733A (en)	1994-06-17	1999-08-03	Corvas International, Inc.	3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
JPH10503176A (ja)	1994-06-17	1998-03-24	コーバスインターナショナル，インコーポレイテッド	酵素インヒビターとしての３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体
US5637599A (en)	1994-06-17	1997-06-10	Corvas International, Inc.	Arginine mimic derivatives as enzyme inhibitors
US5519143A (en)	1994-09-19	1996-05-21	The Du Pont Merck Pharmaceutical Company	Process for the isolation and purification of an imidazole stereoisomer from a mixture of stereoisomers by selective precipitation
US5527827A (en)	1994-10-27	1996-06-18	Merck Frosst Canada, Inc.	Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis
US5552437A (en)	1994-10-27	1996-09-03	Merck Frosst Canada, Inc.	Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5674876A (en)	1995-01-20	1997-10-07	Research Development Foundation	ρ-heteroatom-substituted phenols and uses thereof
JPH08311036A (ja)	1995-03-14	1996-11-26	Takeda Chem Ind Ltd	ピラゾール誘導体、その用途
IL117534A0 (en)	1995-03-24	1996-07-23	Rhone Poulenc Agrochimie	Reagent and process which are useful for grafting a substituted difluoromethyl group onto a compound containing at least one electrophilic function
JPH0912585A (ja)	1995-06-30	1997-01-14	Ube Ind Ltd	高配位典型元素錯体
RO118289B1 (ro)	1995-08-30	2003-04-30	Gd Searle & Co Chicago	Derivati de fenilcarboniluree si compozitie farmaceutica
JPH09124632A (ja)	1995-10-31	1997-05-13	Sankyo Co Ltd	ベンゾヘテロ環誘導体
FR2756825B1 (fr) *	1996-12-10	1999-01-08	Adir	Nouveaux derives [3h]-benzoxazole-2-thiones et [3h]- benzothiazole-2-thiones substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2321244B (en)	1997-01-20	2000-11-22	Pharmacia & Upjohn Spa	Vitamin D3 analogues,process for preparing them,and their use as antiproliferative and antitumour agents
DE19716231A1 (de)	1997-04-18	1998-10-22	Studiengesellschaft Kohle Mbh	Olefinmetathese in komprimiertem Kohlendioxid
DE19722952A1 (de)	1997-05-31	1998-12-03	Huels Chemische Werke Ag	Verwendung von Polymeren zur Inhibierung der Denaturierung von adsorbierten Eiweißstoffen
US5895771A (en)	1997-06-05	1999-04-20	Akzo Nobel Nv	Fluorinated alkoxy and/or aryloxy aluminates as cocatalysts for metallocene-catalyzed olefin polymerizations
US5977413A (en)	1997-08-04	1999-11-02	Nippon Kayaku Kabushiki Kaisha	Method for producing bis(3-amino-4-hydroxyphenyl) compounds
AU9392898A (en)	1997-09-11	1999-03-29	Colorado State University Research Foundation	Weakly coordinating anions containing polyfluoroalkoxide ligands
EP1071648A2 (fr)	1998-03-13	2001-01-31	Merck Frosst Canada & Co.	Acides carboxyliques et acylsulfonamides, compositions contenant ces composes et methodes de traitement
GB2337701A (en)	1998-05-26	1999-12-01	United Medical And Dental Schools Of Guys St Thomas Hospitals	Treatment of ischemia with an angiotensin II antagonist
DE19825182A1 (de) *	1998-06-05	1999-12-09	Agfa Gevaert Ag	Reifung von Silberhalogenidemulsionen
JP2002518380A (ja)	1998-06-18	2002-06-25	ブリストル−マイヤーズスクイブカンパニー	サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
JP2002522082A (ja) *	1998-08-11	2002-07-23	ザ・ガバナーズ・オブ・ザ・ユニバーシティ・オブ・アルバータ	哺乳類マロニルＣｏＡデカルボキシラーゼの阻害剤、作用物質および拮抗物質を同定するための組成物および方法
FR2784114B1 (fr)	1998-09-18	2001-02-02	Thomson Csf	Materiaux polymeres absorbant les composes organophosphores. procede de synthese de ces materiaux. capteurs chimiques comprenant ces materiaux
AU6291999A (en)	1998-10-05	2000-04-26	B.F. Goodrich Company, The	Catalyst and methods for polymerizing cycloolefins
JP2000128878A (ja)	1998-10-28	2000-05-09	Teijin Ltd	ベンゾフリル−α−ピリドン誘導体
ATE298352T1 (de)	1998-12-09	2005-07-15	Sumitomo Bakelite Co	Additionspolymerisation in einer form unter benutzung von polymeren des norbornentyps mit gruppe-3-metallkomplexen
WO2000037422A2 (fr)	1998-12-22	2000-06-29	Neurosearch A/S	Agents de modulation de canaux ioniques
DE69939752D1 (de)	1998-12-23	2008-11-27	Smithkline Beecham Corp	4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
US20030144175A1 (en)	1998-12-23	2003-07-31	Smithkline Beecham Corporation	Protease inhibitors
AU2871900A (en)	1999-02-04	2000-08-25	Millennium Pharmaceuticals, Inc.	G-protein coupled heptahelical receptor binding compounds and methods of use thereof
AU760174B2 (en)	1999-02-09	2003-05-08	Bristol-Myers Squibb Company	Lactam inhibitors of FXa and method
GB9904933D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds
US6316503B1 (en)	1999-03-15	2001-11-13	Tularik Inc.	LXR modulators
US6503949B1 (en) *	1999-05-17	2003-01-07	Noro Nordisk A/S	Glucagon antagonists/inverse agonists
ATE307798T1 (de) *	1999-05-17	2005-11-15	Novo Nordisk As	Glucagon antagonisten/inverse agonisten
AU6074700A (en)	1999-07-08	2001-01-30	Tularik Inc.	Compositions and methods for raising hdl cholesterol levels
WO2001021583A1 (fr)	1999-09-24	2001-03-29	Ono Pharmaceutical Co., Ltd.	Derives d'acide hydroxamique, procede de production desdits derives et medicaments contenant lesdits derives comme principe actif
CZ20024086A3 (cs)	2000-06-14	2003-05-14	Smithkline Beecham Corporation	Inhibitory proteasy
HU227197B1 (en)	2000-10-24	2010-10-28	Richter Gedeon Nyrt	Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JP4503232B2 (ja)	2001-01-26	2010-07-14	中外製薬株式会社	マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法
KR100637564B1 (ko)	2001-01-26	2006-10-20	추가이 세이야쿠 가부시키가이샤	대사 조절자로서 유용한 말로닐-코에이 데카르복실라제억제제
JP4267920B2 (ja)	2001-01-26	2009-05-27	中外製薬株式会社	代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
MXPA03007441A (es)	2001-02-20	2004-10-15	Chugai Pharmaceutical Co Ltd	Azoles como inhibidores de malonil-coa descarboxilasa utiles como modulares metabolicos.
US7709510B2 (en)	2001-02-20	2010-05-04	Chugai Seiyaku Kabushiki Kaisha	Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
ES2353306T3 (es)	2003-08-01	2011-03-01	Chugai Seiyaku Kabushiki Kaisha	Compuestos heterocíclicos útiles como inhibidores de la malonil-coa-descarboxilasa.
EP1648564B1 (fr)	2003-08-01	2007-10-17	Chugai Seiyaku Kabushiki Kaisha	Composes de cyanoamide utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase
JP4773960B2 (ja)	2003-08-01	2011-09-14	中外製薬株式会社	マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノグアニジン型アゾール化合物
DE602004014937D1 (de)	2003-08-01	2008-08-21	Chugai Pharmaceutical Co Ltd	Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer

2002
- 2002-02-19 MX MXPA03007441A patent/MXPA03007441A/es active IP Right Grant
- 2002-02-19 JP JP2002565593A patent/JP4155351B2/ja not_active Expired - Fee Related
- 2002-02-19 DE DE60233650T patent/DE60233650D1/de not_active Expired - Lifetime
- 2002-02-19 WO PCT/US2002/004729 patent/WO2002066034A1/fr active Application Filing
- 2002-02-19 JP JP2002565592A patent/JP4159361B2/ja not_active Expired - Fee Related
- 2002-02-19 KR KR1020037010409A patent/KR100659427B1/ko not_active Expired - Fee Related
- 2002-02-19 HU HU0303272A patent/HU229431B1/hu not_active IP Right Cessation
- 2002-02-19 SI SI200230929T patent/SI1370260T1/sl unknown
- 2002-02-19 ES ES02721032T patent/ES2353686T3/es not_active Expired - Lifetime
- 2002-02-19 CN CNB028052161A patent/CN100383132C/zh not_active Expired - Fee Related
- 2002-02-19 CA CA2437409A patent/CA2437409C/fr not_active Expired - Fee Related
- 2002-02-19 EP EP02721032A patent/EP1370260B1/fr not_active Expired - Lifetime
- 2002-02-19 RU RU2003128307/04A patent/RU2258706C2/ru not_active IP Right Cessation
- 2002-02-19 AU AU2002251987A patent/AU2002251987B2/en not_active Ceased
- 2002-02-19 PL PL362274A patent/PL204456B1/pl not_active IP Right Cessation
- 2002-02-19 WO PCT/US2002/004777 patent/WO2002066035A2/fr not_active Application Discontinuation
- 2002-02-19 US US10/468,378 patent/US7723366B2/en not_active Expired - Fee Related
- 2002-02-19 DE DE60238391T patent/DE60238391D1/de not_active Expired - Lifetime
- 2002-02-19 DK DK02721032.7T patent/DK1370260T3/da active
- 2002-02-19 ES ES02742484T patent/ES2330417T3/es not_active Expired - Lifetime
- 2002-02-19 PT PT02721032T patent/PT1370260E/pt unknown
- 2002-02-19 AT AT02721032T patent/ATE489089T1/de active
- 2002-02-19 NZ NZ526883A patent/NZ526883A/en not_active IP Right Cessation
- 2002-02-19 AT AT02742484T patent/ATE442141T1/de not_active IP Right Cessation
- 2002-02-19 IL IL15682702A patent/IL156827A0/xx unknown
- 2002-02-19 EP EP02742484A patent/EP1379243B1/fr not_active Expired - Lifetime
- 2002-02-19 BR BR0207408-7A patent/BR0207408A/pt not_active IP Right Cessation
2003
- 2003-07-08 IL IL156827A patent/IL156827A/en not_active IP Right Cessation
- 2003-08-19 NO NO20033665A patent/NO20033665L/no not_active Application Discontinuation
2007
- 2007-12-10 JP JP2007318038A patent/JP4842247B2/ja not_active Expired - Fee Related
- 2007-12-17 JP JP2007324412A patent/JP4879152B2/ja not_active Expired - Fee Related
2010
- 2010-12-14 CY CY20101101152T patent/CY1110986T1/el unknown

Also Published As

Publication number	Publication date
PL204456B1 (pl)	2010-01-29
PT1370260E (pt)	2011-02-01
EP1379243A1 (fr)	2004-01-14
JP4159361B2 (ja)	2008-10-01
US7723366B2 (en)	2010-05-25
IL156827A0 (en)	2004-02-08
JP2004522772A (ja)	2004-07-29
WO2002066035A3 (fr)	2002-10-24
DE60238391D1 (de)	2011-01-05
HK1062633A1 (en)	2004-11-19
DE60233650D1 (de)	2009-10-22
HUP0303272A2 (hu)	2004-01-28
CN1492762A (zh)	2004-04-28
CA2437409A1 (fr)	2002-08-29
ATE489089T1 (de)	2010-12-15
RU2003128307A (ru)	2005-03-10
PL362274A1 (en)	2004-10-18
EP1370260B1 (fr)	2010-11-24
MXPA03007441A (es)	2004-10-15
EP1379243B1 (fr)	2009-09-09
CA2437409C (fr)	2010-10-19
ATE442141T1 (de)	2009-09-15
AU2002251987B2 (en)	2005-02-17
JP4879152B2 (ja)	2012-02-22
BR0207408A (pt)	2004-02-25
KR100659427B1 (ko)	2006-12-18
ES2330417T3 (es)	2009-12-10
KR20030077015A (ko)	2003-09-29
WO2002066034A1 (fr)	2002-08-29
US20040082564A1 (en)	2004-04-29
CN100383132C (zh)	2008-04-23
WO2002066035A2 (fr)	2002-08-29
ES2353686T3 (es)	2011-03-04
CY1110986T1 (el)	2015-06-11
NO20033665D0 (no)	2003-08-19
JP4842247B2 (ja)	2011-12-21
DK1370260T3 (da)	2011-03-14
HU229431B1 (en)	2013-12-30
IL156827A (en)	2013-12-31
JP2008120816A (ja)	2008-05-29
JP4155351B2 (ja)	2008-09-24
SI1370260T1 (sl)	2011-02-28
JP2004522773A (ja)	2004-07-29
NZ526883A (en)	2005-11-25
HUP0303272A3 (en)	2007-03-28
RU2258706C2 (ru)	2005-08-20
EP1370260A2 (fr)	2003-12-17
JP2008115188A (ja)	2008-05-22

Publication	Publication Date	Title
NO20033665D0 (no)	2003-08-19	Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
ATE509014T1 (de)	2011-05-15	Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
ATE341539T1 (de)	2006-10-15	Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
TW200505423A (en)	2005-02-16	Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EA201001669A1 (ru)	2011-06-30	Замещенные пиримидин-5-карбоксамиды 281
ATE477256T1 (de)	2010-08-15	Thienylverbindungen
ATE433981T1 (de)	2009-07-15	Heterocyclische verbindungen
SE0202463D0 (sv)	2002-08-14	Novel compounds
BR0306872A (pt)	2005-09-06	Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2
ATE484508T1 (de)	2010-10-15	Furylverbindungen
EA200970486A1 (ru)	2009-10-30	Соединения для ингибирования митоза
NO20050016L (no)	2005-03-01	Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
DK1519724T3 (da)	2010-01-04	Fredericamycin-derivater som lægemidler til behandling af tumorer
IS2517B (is)	2009-06-15	Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
DK1506185T3 (da)	2006-10-02	Forbindelser og deres anvendelse som 5-HT-inhibitorer
DE60323765D1 (de)	2008-11-06	Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
SE0302756D0 (sv)	2003-10-17	Novel Compounds
TW200508195A (en)	2005-03-01	3-aminopyrrolidines as inhibitors of monoamine uptake
ITMI20042475A1 (it)	2005-03-23	Uso di derivati tiazolidinonici come agenti terapeutici
MXPA05006408A (es)	2006-03-08	Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
AR057403A1 (es)	2007-12-05	4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
NO20062700L (no)	2006-08-08	Morfolinderivater som norepinefrin reopptaksinhibitorer
MXPA06002778A (es)	2006-06-14	Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
SE0302253D0 (sv)	2003-08-21	Lipase-colipase inhibitor

Legal Events

Date	Code	Title	Description
2013-07-15	FC2A	Withdrawal, rejection or dismissal of laid open patent application